Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Fulvestrant 10Letrozole 4Alpelisib 4ribociclib 3palbociclib 3Paclitaxel 2NVP-BKM120 2volagidemab 1serabelisib 1sapanisertib 1olaparib 1liposomal doxorubicin 1gedatolisib 1exemestane 1dapagliflozin 1capivasertib 1abemaciclib 1Taxes 1Tamoxifen 1Secretin 1STX-478 1Metformin 1Lomustine 1Leuprolide 1Irinotecan 1Imlunestrant 1Goserelin 1Gemcitabine 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × CYH33 × Breast × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡